BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Vaxcyte (PCVX)VaxcyteEarnings

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026.

Related news

PCVXVaxcyte2026-02-24 21:05 EST

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

VXRTVaxart2026-08-06 20:05 EST

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

VXRTVaxart2026-05-07 20:05 EST

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

GSKGSK plc2025-04-30 07:00 EST

GSK makes strong start to 2025 with growth in sales, profits and earnings

GSKGSK plc2025-05-29 13:54 EST

GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-10-07 02:49 EST

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 20:28 EST

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 10:00 EST

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

PCVXVaxcyte2026-10-04 21:00 EST

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

PCVXVaxcyte2026-09-03 20:05 EST

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Stock data

Close
66.70 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States